Abstract
Introduction Currently, sub-second monitoring of neurotransmitter release in humans can only be performed during standard of care invasive procedures like DBS electrode implantation. The procedure requires acute insertion of a research probe and additional time in surgery, which may increase infection risk. We sought to determine the impact of our research procedure, particularly the extended time in surgery, on infection risk.
Methods We screened 607 DBS electrode implantation procedures performed at Wake Forest Baptist Medical Center between January 2011 through October 2020 using International Classification of Diseases (ICD) codes for infection. During this period, 116 cases included an IRB approved 30-minute research protocol, during the DBS electrode implantation surgery, to monitor sub-second neurotransmitter release. We used Fisher’s Exact test (FET) to determine if there was a significant change in the infection rate following DBS electrode implantation procedures that included, versus those that did not include, the neurotransmitter monitoring research protocol.
Results Within 30-days following DBS electrode implantation, infection was observed in 7 (1.43%) out of 491 procedures that did not include the research procedure and 2 (1.72%) of the 116 procedures that did include the research procedure. Total infection rates (i.e., not constrained by 30-day time window) for all non-research cases was 28/491 (5.70%) and only 4/116 (3.45%) for research inclusive cases. Notably, all types of infection observed were typical of those expected for DBS electrode implantation.
Conclusion Total infection rates are not statistically different in patients who performed the research procedure (3.45% vs. 5.70%; p = 0.4872, FET) and not statistically different across research and non-research groups within 30-days following the research procedure (1.72% vs. 1.43%; p = 0.684, FET). Our results demonstrate that the research procedures used for sub-second monitoring of neurotransmitter release in humans can be performed without increasing the rate of infection.
Competing Interest Statement
Dr. Ihtsham ul Haq has received salary support for research from Allergan, Boston Scientific, Great Lakes Neurotechnology, and Pfizer. He has consulted for compensation for Boston Scientific and Medtronics. He has received funding from the NINDS, the NIAA, and the Parkinson's Foundation. Dr. Mustafa Siddiqui has received research support as a site Principal Investigator for clinical trials from Neuraly, University of Rochester, Michael J. Fox-Neuropoint Alliance, Theravance Biopharma, Impax Laboratories, Sun Pharma, Abbvie, Boston Scientific Neuromodulation, Biogen and Sunovion. He has received honoraria or non-financial support as scientific advisor from Abbvie and Boston Scientific Neuromodulation. Dr. Adrian Laxton is a consultant and member of the safety committee for Monteris Medical. Dr. Stephen Tatter has received research support as a Principal Investigator for clinical trials from from Arbor Pharmaceuticals and Monteris Medical, Inc. This work is supported by Brittany Liebenow's funding from the NIH: F30DA053176. This work is supported by Dr. Kenneth T. Kishida's funding from the NIH: R01DA048096, R01MH121099, R01NS092701, R01MH124115, and KL2TR001421. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors have no conflicts of interest to declare.
Funding Statement
This work is supported by Brittany Liebenow's funding from the NIH: F30DA053176. This work is supported by Dr. Kenneth T. Kishida's funding from the NIH: R01DA048096, R01MH121099, R01NS092701, R01MH124115, and KL2TR001421. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at Wake Forest University Health Sciences approved all procedures described for this retrospective study (IRB00064371) and for our ongoing research protocol in the DBS operating room (IRB00017138). Under IRB00017138, research participants gave their written informed consent prior to participation in the research study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data reported in this manuscript are not publicly available due to containing identifying information that would compromise the privacy of patients and research participants whose data are deidentified and summarized in this study.
